ArticleScientific reports2025
Crotonylation deficiency of S100A7 K49 promotes psoriatic keratinocyte proliferation through enhanced interaction with RAGE.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CAB39 K196 Decrotonylation Drives Psoriasis Pathogenesis by Modulating Keratinocyte Proliferation and Glycolysis.Journal of cellular physiology · 2026Article
- Review
- Epigenetic regulatory mechanisms of autoimmune skin diseases: novel biomarkers and therapeutic prospects.Clinical epigenetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Psoriasis is a chronic inflammatory dermatosis characterized by the hyperproliferative of keratinocytes. S100A7 plays a pivotal role in the pathogenesis of psoriasis. Lysine crotonylation of proteins is a newly identified modification that impacts diverse biological processes and its dysregulation has been implicated in autoimmune diseases. To investigate the profile of lysine crotonylation and its pathogenic role in psoriasis, we conducted a comparative analysis of crotonylation-modified proteins in psoriatic lesions versus healthy controls. Mutant keratinocytes with crotonylation deficiency of S100A7 were generated to explore its functional effects in psoriasis. Our omic analysis revealed a unique lysine crotonylation profile in psoriatic lesions, with a notable downregulation of crotonylation at lysine 49 (K49) of S100A7. In vitro studies demonstrated that S100A7-K49A crotonylation deficiency exhibited enhanced cell viability, augmented glycolytic metabolism, and upregulated expression of key metabolic enzymes. Furthermore, co-immunoprecipitation assays demonstrated that the K49 crotonylation-deficient form of S100A7 strengthens its interaction with RAGE, leading to enhanced phosphorylation of AKT and mTOR. Our findings suggest that S100A7 K49 crotonylation deficiency plays a pivotal role in promoting keratinocytes proliferation and metabolic reprogramming in psoriasis, and targeting abnormal S100A7 crotonylation as a potential therapeutic strategy for intervention in psoriasis-related pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.